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D1-like dopamine receptor activation and natriuresis by nitro- proximal tubule, the overall increase in sodium excretion
catechol COMT inhibitors. produced by dopamine and D1-like receptor agonists
Background. In recent years, several nitrocatechol deriva- results from inhibition of main sodium transport mecha-tives (tolcapone, entacapone, and nitecapone) have been devel-
nisms at the basolateral and apical membranes, respec-oped and found to be highly selective and potent inhibitors of
tively, Na1,K1-ATPase [2, 3] and Na1/H1 exchanger [4].catechol-O-methyltransferase (COMT). More recently, natri-
uretic properties were described for two of these compounds (en- The proximal tubules, but not distal segments of the
tacapone and nitecapone), although this was not accompanied by nephron, are endowed with a high aromatic L-amino
enhanced urinary excretion of dopamine. We hypothesized that acid decarboxylase (AADC) activity, and epithelial cells
nitrocatechol derivatives stimulate D1-like dopamine receptors. of proximal tubules have been demonstrated to synthe-Methods. Adult male Wistar rats were treated with a nitrocat-
size dopamine from circulating or filtered L-3,4-dihy-echol COMT inhibitor (entacapone, tolcapone, or nitecapone,
30 mg/kg, orally), and the urinary excretion of dopamine and droxyphenylalanine (L-DOPA) [3, 5, 6]. One of the most
sodium was quantitated. The interaction of nitrocatechol deriv- important factors in determining the synthesis of dopa-
atives with D1-like receptors was evaluated by their ability to mine is the amount of sodium delivered to the kidney
displace [3H]-Sch23390 binding from membranes of rat renal
[3, 5, 6]. However, high levels of enzymes involved in thecortex and cAMP production in opossum kidney (OK) cells.
metabolic degradation of renal dopamine, such as typesResults. Urinary excretion of sodium (mmol/h) was markedly
A and B monoamine oxidases (MAO-A and MAO-B)increased by all three nitrocatechol derivatives: vehicle, 55.0 6
5.6; entacapone, 98.4 6 9.3; tolcapone, 97.5 6 9.3; and niteca- and catechol-O-methyltransferase (COMT) [7–10], may
pone, 120.5 6 12.6. Pretreatment with the selective D1 antago- determine the overall availability of the amine.
nist Sch 23390 (60 mg/kg) completely prevented their natri- More recently, the administration of a new class ofuretic effects. Nitecapone and tolcapone were equipotent (IC50s
COMT inhibitors (the nitrocatechol derivatives niteca-of 48 and 42 mmol/L) and more potent than entacapone and do-
pone and entacapone) was shown to be accompanied bypamine (IC50s of 107 and 279 mmol/L) in displacing [3H]-Sch23390
binding. In OK cells, all three nitrocatechol derivatives signifi- marked natriuresis and a parallel reduction of Na1,K1-
cantly increased cAMP accumulation and reduced Na1/H1 ex- ATPase activity [11–13]. These effects were prevented
change and Na1,K1-ATPase activities, this being prevented by by selective blockade of dopamine D1 receptors, but werea blockade of D1-like receptors. not accompanied by parallel increases in the urinaryConclusion. Stimulation of D1-like dopamine receptors and
excretion of dopamine. An increase in the urinary excre-inhibition of Na1/H1 exchange and Na1,K1-ATPase activities
by nitrocatechol COMT inhibitors may contribute to natri- tion of 3,4-dihydroxyphenylacetic acid (DOPAC) was
uresis produced by these compounds. also observed after COMT inhibition [12], which is the
expected result following the inhibition of dopamine
O-methylation in the kidney [8]. An increase in the renal
Dopamine of renal origin exerts natriuretic and di- dopaminergic tonus produced by the nitrocatechol
uretic effects by activating D1-like receptors located at COMT inhibitors was thus given as explanation for their
various regions in the nephron [1]. At the level of the natriuretic effects [11–13]. However, CGP 28014, a pyri-
dine derivative also endowed with marked inhibitory
effects on COMT, failed to affect the urinary excretionKey words: diuretics, sodium transport, renal dopamine, signal trans-
duction, receptor-mediated natriuresis. of sodium [12]. Because nitrocatechol derivatives, but
not CGP 28014, are chemically related to dopamine (Fig.Received for publication June 14, 2000
1), it was hypothesized that their natriuretic effects couldand in revised form November 14, 2000
Accepted for publication November 17, 2000 be related to the direct activation of dopamine receptors
rather than an enhanced availability of renal dopamine.Ó 2001 by the International Society of Nephrology
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Fig. 1. Chemical structure of dopamine, tol-
capone [5-(p-tolylcarbonyl)-3-nitrocatechol],
entacapone [5-(N,N-diethyl-39-amino-29-cyano-
39-oxopropyl-19-en)-3-nitrocatechol], and ni-
tecapone [5-(29,29-dicyanoethyl-19-en)-3-nitro-
catechol].
The aim of the present work was to evaluate whether lites. At t 5 0 min, animals (N 5 8 in each group) were
natriuresis produced by nitrocatechol derivatives is de- given the COMT inhibitor (tolcapone, entacapone, and
pendent on the enhanced availability of renal dopamine nitecapone, 30 mg/kg, orally) or vehicle (10% Tween
or direct stimulation of dopamine receptors. For this 80, in saline). Fifteen minutes later, all animals were
purpose, a series of experiments was conducted in both in submitted to an oral hydration (tap water, 20 mL/kg,
vivo and in vitro conditions in which three nitrocatechol orally) in order to promote diuresis. In some experimen-
derivatives (tolcapone, entacapone, and nitecapone) tal groups, rats were given the D1 antagonist Sch 23,390
were tested for their ability to produce D1-like receptor- (2 3 30 mg/kg, IP in saline) 15 minutes before the admin-
mediated natriuresis and inhibition of sodium renal tubu- istration of COMT inhibitors (that is, at t 5 215 min;
lar transport mechanisms, namely Na1/H1 exchange and before being placed in the metabolic cage) and repeated
Na1,K1-ATPase activities. The interaction of nitrocate- three hours later (at t 5 180 min). After completion of
chol derivatives with D1-like receptors was also evaluated this protocol, the rats were removed from the metabolic
by their ability to interfere with the binding of [3H]-Sch cages and anesthetized with sodium pentobarbital (60
23390 to rat renal cortical membranes and D1-like– mg/kg, IP). Blood from the vena cava was then collected
coupled signal transduction pathways, namely adenylyl in tubes containing heparin for later determination of
cyclase activation. We report that all three nitrocatechol catecholamines, electrolytes, and creatinine in plasma.
derivatives interact with D1 receptors, increase cyclic
AMP (cAMP) production, and inhibit Na1/H1 exchange Renal COMT activity
and Na1,K1-ATPase activities, which might explain their
Renal COMT activity was assessed in rats given tolca-
D1-like receptor-mediated natriuresis. pone, entacapone, and nitecapone (30 mg/kg, orally) or
the vehicle (10% Tween 80 in saline) one hour after
METHODS the administration. COMT activity was evaluated by the
ability of kidney homogenates to methylate epinephrineAnimals and experimental protocol
to metanephrine, as previously described [14].Male 50-day-old Wistar rats (Interfauna Ibe´rica, Bar-
celona, Spain) weighing 195 to 207 g were used in the
D1-like binding to rat kidney membranesexperiments. All animals were fed ad libitum throughout
The radioligand [3H]-Sch 23390, a D1-like selective an-the study with ordinary rat chow containing 0.4% sodium
tagonist, was used for the evaluation of D1-like binding in(Letica, Barcelona, Spain). On the day of the experiment,
rat kidney membranes, prepared as previously describedanimals were kept in metabolic cages for six hours, with
[15]. Binding experiments were performed in quadrupli-food consumption, water intake, and urine volume moni-
cates in 96-well EIA/RIA plates (Costar, Cambridge,tored throughout the study. The vials used to collect
MA, USA) in a final volume of 0.2 mL binding bufferurine contained 1 mL of 6 mol/L HCl to prevent sponta-
neous decomposition of monoamines and amine metabo- containing 2.5 nmol/L [3H]-Sch 23390 and 100 to 200 mg
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membrane protein, and increasing concentrations of the the pH indicator acetoxymethyl ester 29,79-bis(carboxy-
ethyl)-5(6)-carboxyfluorescein (BCECF-AM). At daysCOMT inhibitors or dopamine. Nonspecific binding was
determined in the presence of 10 mmol/L of unlabeled 6 to 8 after seeding, the cells cultured in 96-well plates
were incubated at 378C for 40 minutes with 5 mmol/LSch 23390 [16, 17]. After 30 minutes of incubation at
308C in a shaking water bath, assays were terminated by BCECF-AM. The cells were then washed twice with pre-
warmed dye-free–modified Krebs buffer (buffer compo-vacuum filtration through glass fiber filtermats with the
Brandel 96 cell Harvester (Brandel, Gaithersburg, MD, sition in mmol/L: NaCl, 140; KCl, 5.4; CaCl2, 2.8; MgSO4,
1.2; NaH2PO4, 0.3; KH2PO4, 0.3; HEPES, 10; glucose, 5;USA). Filters were washed three times with 200 mL of
cold 50 mmol/L Tris-HCl, pH 7.4, and were dried and pH 7.4, adjusted with Tris base) before initiation of the
fluorescence recordings. Test compounds were added toimpregnated with MeltiLex A (Wallac; Pharmacia, Upp-
sala, Sweden) and disintegrations per minute (DPM) the extracellular fluid 15 minutes before starting the so-
dium-dependent pHi recovery period. Cells were placed indetermined in a Microbeta counter (Wallac) with 20%
efficiency. the sample compartment of a dual-scanning microplate
spectrofluorometer (Spectramax Gemini; Molecular De-
Cell culture vices, Sunnyvale, CA, USA), and fluorescence was mea-
Opossum kidney (OK) cells (ATCC 1840-HTB) were sured every 19 seconds alternating between 440 and 490
obtained from the American Type Culture Collection nm excitation at 535 nm emission, with a cutoff filter of
(Rockville, MD, USA) and were maintained in a humidi- 530 nm. The ratio of intracellular BCECF fluorescence
fied atmosphere of 5% CO2/95% air at 378C. OK cells at 490 and 440 nm was converted to [pH]i by comparison
(passages 63 to 73) were grown in Minimal Essential Me- with values from an intracellular calibration curve using
dium (Sigma Chemical Co., St. Louis, MO, USA) supple- the nigericin (10 mmol/L) and high-K1 method [21].
mented with 100 U/mL penicillin G, 0.25 mg/mL ampho-
Electrogenic ion transport in OK cellstericin B, 100 mg/mL streptomycin (Sigma), 10% fetal
bovine serum (FBS; Sigma), and 25 mmol/L N-2-hy- Opossum kidney cells grown on polycarbonate filters
(Snapwell; Costar) were mounted in Ussing chambersdroxyethylpiperazine-N9-2-ethanosulfonic acid (HEPES;
Sigma). For 24 hours prior to each experiment, the cell (window area 1.0 cm2) equipped with water-jacketed gas
lifts bathed on both sides with 10 mL of Krebs-Hensleitmedium was free of FBS. The experiments were per-
formed two to three days after cells reached confluence solution, gassed with 95% O2 and 5% CO2, and main-
tained at 378C. The Krebs-Hensleit solution containedand seven to eight days after the initial seeding, and each
cm2 contained approximately 100 mg of cell protein. (in mmol/L) NaCl 118, KCl 4.7, NaHCO3 25, KH2PO4
1.2, CaCl2 2.5, MgSO4 1.2; pH was adjusted to 7.4 after
Assay of cAMP gassing with 5% CO2 and 95% O2. Monolayers were con-
Cyclic AMP was determined with an enzyme immuno- tinuously voltage clamped to zero potential differences
assay kit (Assay Designs, Inc., Ann Arbor, MI, USA), by application of external current, with compensation
as previously described [18]. Opossum kidney (OK) cells for fluid resistance, by means of an automatic voltage
were preincubated for 15 minutes at 378C in Hanks’ me- current clamp (DVC 1000; World Precision Instruments,
dium (medium composition, in mmol/L: NaCl 137, KCl Sarasota, FL, USA). Transepithelial resistance (V · cm2)
5, MgSO4 0.8, Na2HPO4 0.33, KH2PO4 0.44, CaCl2 0.25, was determined by altering the membrane potential step-
MgCl2 1.0, Tris HCl 0.15, and sodium butyrate 1.0, pH wise (63 mV) and applying the ohmic relationship. The
7.4), containing 100 mmol/L 3-isobutyl-1-methylxanthine voltage/current clamp unit was connected to a personal
(IBMX), a phosphodiesterase inhibitor, in the presence computer via a BIOPAC MP1000 data acquisition sys-
or absence of antagonists. Cells were then incubated tem (BIOPAC Systems, Inc., Goleta, CA, USA). Data
for 15 minutes with dopamine or specific dopaminergic analysis was performed using AcqKnowledge 2.0 soft-
agonists. At the end of the experiment, the reaction was ware (BIOPAC Systems, Inc.). Cell monolayers were
stopped by the addition of 0.1 mol/L HCl. Aliquots were continuously monitored for changes in short circuit cur-
taken for the measurement of total cAMP content. rent (Isc, mA/cm2) after the addition of amphotericin B
to the apical-side reservoir, to increase the sodium deliv-
Na1/H1 exchanger activity ered to Na1,K1-ATPase at the saturating level. Under
Na1/H1 exchanger activity was assayed as the ability to short-circuit conditions, the resulting current was due to
achieve full pHi recovery after an acid load imposed by the transport of sodium across the basolateral membrane
10 mmol/L NH4Cl, followed by removal of sodium from mediated by Na1,K1-ATPase, as indicated by complete
the Krebs modified buffer solution, in the absence of prevention by ouabain (100 mmol/L) and removal of
sodium from the medium bathing the apical side of theCO2/HCO3 [19, 20]. In these experiments, NaCl was re-
placed by an equimolar concentration of tetramethylam- monolayer. Test compounds were added to the fluid
bathing the apical and basal cell sides 20 minutes beforemonium chloride (TMA). Intracellular pH was measured
by means of spectrofluorometry in OK cells loaded with the addition of amphotericin B.
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Na1,K1-ATPase assay in rat renal proximal tubules Drugs
The compounds used were as follows: 3,4 dihydroxy-Na1,K1-ATPase activity in rat renal proximal tubules,
prepared as described previously [22], was measured by phenylacetic acid (DOPAC), L-3,4 dihydroxyphenylala-
nine (L-DOPA), dopamine hydrochloride, homovanillicthe method of Quigley and Gotterer [23], with minor
modifications. Briefly, isolated rat renal proximal tubules acid (HVA), 5-hydroxyindolacetic acid, isobutylmethyl-
xanthine, and ouabain (all from Sigma Chemical Com-were preincubated for 20 minutes at 378C in the absence
and the presence of test compounds. After the preincu- pany); Sch 23390 and SKF 83566 (RBI, Natick, MA,
USA); [3H]-Sch 23390 ([N-methyl-3H] R[1]-7-chloro-bation period, the renal tubules were permeabilized by
rapid freezing in dry ice-acetone and thawing. The reac- 2,3,4,5-tetrahydro-3-methyl-1-phenyl-1H-3 benzazepine-
8-ol, specific activity 2600 to 3200 GBq/mmol; Newtion was initiated by the addition of 4 mmol/L adenosine
59-triphosphate (ATP). For determination of ouabain- England Nuclear, Boston, MA, USA); BCECF-AM acet-
oxymethyl ester and nigericin (Molecular Probes, Eugene,sensitive ATPase, NaCl and KCl were omitted, and Tris-
HCl (150 mmol/L) and ouabain (1 mmol/L) were added OR, USA); and tolcapone, entacapone, and nitecapone
(synthesized in the Department of Chemistry, BIAL, S.to the assay. After incubation at 378C for 15 minutes, the
reaction was terminated by the addition of 50 mL of ice- Mamede do Coronado, Portugal).
cold trichloroacetic acid. Samples were centrifuged (3000
Statisticsr.p.m.), and liberated Pi in supernatant was measured by
spectrophotometry at 740 nm. Na1,K1-ATPase activity Arithmetic means are given with SEM or geometric
means with 95% confidence values. Statistical analysis waswas expressed as nanomoles Pi per milligram protein
per minute and determined as the difference between performed by one-way analysis of variance (ANOVA)
followed by Newman–Keuls test for multiple compari-total and ouabain-insensitive ATPase. The protein con-
tent in cell suspension (,2 mg/mL), as determined by the sons. A P value of less than 0.05 was assumed to denote
a significant difference.method described by Bradford [24] with human serum
albumin as a standard, was similar in all samples.
RESULTSAssay of catecholamines
Previous studies on the natriuretic effects of niteca-The measurement of catecholamines and its metabo-
pone and entacapone were performed using a 30 mg/kglites in urine and plasma samples and metanephrine in
dose [11, 12]. To make sure this dose was effective insamples used for the assay of renal COMT was performed
inhibiting renal COMT, enzyme activity was evaluatedby high-pressure liquid chromatography with electro-
in kidney homogenates one hour after the administrationchemical detection, as previously described [14, 25]. In
of tolcapone, entacapone, or nitecapone (all at 30 mg/kg,brief, aliquots of 0.5 mL of acidified urine or plasma were
orally) and in vehicle (10% Tween 80, in saline)-treatedplaced in 5 mL conical-based glass vials with 50 mg alu-
rats. Using a saturating concentration of the substratemina, and the pH of the samples was adjusted to pH 8.6
(epinephrine, 500 mmol/L), the formation of metaneph-by addition of Tris buffer. The adsorbed catecholamines
rine in control animals was 36.9 6 4.0 nmol/mg protein/h.were then eluted from the alumina with 200 mL of 0.2 mol/L
Treatment with tolcapone, entacapone, and nitecaponeperchloric acid on Costar Spin-X microfilters; 50 mL of the
resulted in 99.1 6 0.2, 98.8 6 0.2, and 98.1 6 0.5%eluate were injected into a high-pressure liquid chromato-
enzyme inhibition, respectively.graph (Gilson Medical Electronics, Villiers le Bel, France).
The administration of tolcapone, entacapone, and ni-For the quantitation of homovanillic acid (HVA) in urine
tecapone (all at 30 mg/kg, orally) resulted in significantsamples and metanephrine in samples used for the assay
decreases in the urinary excretion of HVA and significantof renal COMT, 50 mL of urine or the supernatant were
increases in the urinary excretion of DOPAC (Fig. 2).diluted to 500 mL with perchloric acid (0.2 mol/L), filtered
However, the administration of tolcapone and entaca-on Costar Spin-X microfilters, and directly injected into
pone did not change the urinary excretion of dopamine,the chromatograph. The lower limit of detection of L-
whereas nitecapone produced a twofold increase in uri-DOPA, dopamine, norepinephrine, metanephrine, DO-
nary dopamine (Fig. 2). No significant changes were ob-PAC, and HVA ranged from 350 to 1000 fmol.
served in the urinary excretion of L-DOPA with either
Plasma and urine ionogram and biochemistry compound. Levels of L-DOPA in plasma (in pmol/mL)
in control animals (5.7 6 0.6) did not differ from those inUrinary sodium and potassium were measured by flame
tolcapone-treated (6.5 6 1.9), entacapone-treated (4.8 6photometry (model FML3) connected to a dilutor (model
0.4), and nitecapone-treated (3.9 6 0.7) animals.A 6241; Radiometer, Copenhagen, Denmark). Urine
Inhibition of renal COMT with either tolcapone, enta-and plasma creatinine levels were measured by a wave-
capone, or nitecapone was accompanied by marked (P ,length photometer (Hitashi Automatic Analizer, model
717, or a Beckman Analyzer II). 0.05) increases in the urinary excretion of sodium when
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Fig. 2. Urinary excretion (in nmol/h) of (A)
L-DOPA, (B) dopamine, (C ) DOPAC, and
(D) HVA in rats given a nitrocatechol deriva-
tive (tolcapone, entacapone, and nitecapone,
30 mg/kg, orally) or vehicle (10% Tween 80
in saline). Symbols are: (h) control; (j) tolca-
pone; ( ) entacapone; ( ) nitecapone. The
columns represent means 6 SEM (N 5 8).
*P , 0.05, significantly different from corre-
sponding control values.
Fig. 3. Effects of tolcapone (Tol), entaca-
pone (Ent), and nitecapone (Nit; all at 30
mg/kg, orally) on the urinary excretion of so-
dium (in mmol/h) in vehicle and Sch 23390
(Sch; 2 3 30 mg/kg, intraperitoneally)-treated
rats; control animals were given the vehicle
(10% Tween 80 in saline). Columns represent
mean 6 SEM (N 5 8). *P , 0.05, significantly
different from corresponding control values;
#P , 0.05, values for entacapone, tolcapone,
or nitecapone.
compared with vehicle-treated rats (Fig. 3). These natri- with tolcapone, entacapone, and nitecapone (data not
shown). The urinary volume in control rats (3.3 6uretic effects were abolished by pretreatment with the
D1-like receptor antagonist (Sch 23390). As expected, 0.5 mL) was not significantly different from that observed
in rats treated with tolcapone (4.2 6 0.8 mL), entacaponethe fractional excretion of sodium (FENa) in rats treated
with tolcapone (1.4 6 0.2%), entacapone (1.4 6 0.1%), (4.8 6 0.6 mL), and nitecapone (4.6 6 0.4 mL). Sodium,
potassium, and creatinine in plasma of controland nitecapone (1.6 6 0.2%) was greater (P , 0.05)
than that in control animals (0.8 6 0.2%). The adminis- animals (145.5 6 11.1 mmol/L, 4.9 6 0.2 mmol/L, and
0.4 6 0.5 mg/dL, respectively) did not differ from thattration of Sch 23390 alone failed to alter the FENa
(1.0 6 1%). The urinary excretion of potassium (88 6 in rats treated with either nitrocatechol derivative (data
not shown).7 mmol/hour) and creatinine (0.20 6 0.02 mg/hour) in
control rats was similar to that observed in rats treated The next series of experiments evaluated whether these
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Fig. 4. Competition for specific binding of
[3H]-Sch 23390 by dopamine, tolcapone, enta-
capone, and nitecapone in membranes of rat
renal cortex. Symbols represent mean 6 SEM
(N 5 4 to 8).
nitrocatechol derivatives directly interact with the D1- ment of [3H]-Sch 23390 with an IC25 value of 147 (72 to
303) mmol/L.like subtype of dopamine receptors. For that purpose,
all three nitrocatechol derivatives and dopamine were To obtain information on the type of interaction ef-
fect of tolcapone, entacapone, and nitecapone on D1-tested on their ability to displace [3H]-Sch 23390, one of
the most selective D1-like antagonists, from rat renal cor- like receptors, it was thought appropriate to measure
cAMP accumulation, as a measure of D1-like receptortical membranes. As shown in Figure 4, all three nitrocat-
echol derivatives, tolcapone, entacapone, and niteca- activation. As shown in Figure 5, dopamine (1 mmol/L)
and all three nitrocatechol derivatives (100 mmol/L) in-pone (0.3 to 1000 mmol/L), were found to displace, in a
concentration-dependent manner, [3H]-Sch 23390 from creased cAMP accumulation in OK cells, this being
sensitive to the selective D1-like receptor antagonist SKFrat renal cortical membranes. Considering that the maxi-
mal effect was a displacement of 50% of the specific 83566 (1 mmol/L). Baseline cAMP levels were 6.4 6
0.9 pmol/mg protein (N 5 8).binding, IC25 values for tolcapone, entacapone, and nite-
capone were 38 (range 19 to 79) mmol/L, 60 (24 to Na1/H1 exchange activity was assayed as the ability
to achieve full pHi recovery after an acid load followed149) mmol/L, and 65 (21 to 196) mmol/L. Dopamine
(0.3 to 1000 mmol/L), using the same experimental con- by sodium removal. To promote an artificial acidifica-
tion, OK cells were incubated for five minutes in theditions, produced a concentration dependent displace-
Vieira-Coelho et al: Nitrocatechol inhibitors 1689
Fig. 5. Effect of dopamine (1 mmol/L), tolca-
pone (100 mmol/L), entacapone (100 mmol/L),
and nitecapone (100 mmol/L) alone or in the
presence of SKF 83566 (10 mmol/L) on cAMP
accumulation in OK cells. *P , 0.05, signifi-
cantly different from corresponding basal val-
ues; #P , 0.05, values for entacapone, tolca-
pone, or nitecapone.
presence 10 mmol/L NH4Cl followed by sodium removal
from the Krebs modified buffer solution for another five
minutes. After this period, sodium was added to the cells,
and pHi was able to recover to baseline values (Fig. 6).
In contrast, in cells treated with dopamine (1 mmol/L),
the sodium-dependent recovery of pHi was markedly
attenuated, this being prevented by pretreatment with
the D1-like receptor antagonist SKF 83566 (1 mmol/L).
This effect was mimicked by tolcapone, entacapone, and
nitecapone (Fig. 7). The effect of nitrocatechol deriva-
tives (100 mmol/L) on pHi recovery was completely pre-
vented by pretreatment with the D1-like selective antago-
nist SKF 83566 (1 mmol/L; Fig. 7). Table 1 depicts the
pHi recovery rates (in pH units/sec) during the linear
phase of pH recovery after intracellular acidification.
To study Na1,K1-ATPase activity in OK cells, we used
Fig. 6. Assessment of Na1/H1 exchange activity as the Na1-dependentan eletrophysiological method in which cell monolayers
recovery of pHi after an acid load imposed by the 10 mmol/L NH4Clwere continuously monitored for changes in Isc after the pulse followed by sodium removal [NaCl was substituted by an equimo-
lar concentration of tetramethylammonium chloride (TMA Cl)] in opos-addition of amphotericin B to the apical cell side, to in-
sum kidney (OK) cells. Symbols are (d) pHi before and after the acidcrease the sodium delivered to Na1,K1-ATPase to the
load; (h) baseline pHi throughout the study in cells that were notsaturating level. As shown in Figure 8A, the addition of submitted to an acid load. The symbols represent means of 8 to 12
experiments; the vertical lines indicate SEM.amphotericin B increased Isc in a concentration-depen-
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Fig. 7. Recovery of pHi after an acid load
imposed by the 10 mmol/L NH4Cl pulse fol-
lowed by sodium removal in control condi-
tions (d) and in OK cells treated with tolca-
pone (100 mmol/L; B), entacapone (100 mmol/L;
C ), nitecapone (100 mmol/L; D), and dopa-
mine (1 mmol/L; A) alone (h) or in combina-
tion with SKF 83566 (j; 1 mmol/L). The sym-
bols represent means of four experiments; the
vertical lines indicate SEM.
Table 1. Effect of dopamine (1 mmol/L), tolcapone (100 mmol/L), the apical cell side significantly reduced the effect of
entacapone (100 mmol/L), and nitecapone (100 mmol/L) alone or 0.6 mg/mL amphotericin B on Isc, this being preventedin combination with SKF 83566 (1 mmol/L) on slope values for pHi
by the D1-like receptor antagonist SKF 83566 (1 mmol/L;recovery after an acid load (10 mmol/L NH4Cl followed by sodium
removal) in OK cells Fig. 8B). Tolcapone, entacapone, and nitecapone were
also found to attenuate the effect of amphotericin B ondpHi/dt
Isc in a concentration-dependent manner (Fig. 9), in whichpH units/s
the effects were prevented by SKF 83566 (1 mmol/L).Control 0.00193360.000121
In a final series of experiments, it was decided to evalu-Dopamine 0.00088760.000073a
SKF 835661dopamine 0.00128260.000172b ate the effects of all three nitrocatechols on Na1,K1-
Tolcapone 0.00123960.000266a ATPase activity in rat renal proximal tubules. For thisSKF 835661 tolcapone 0.00249960.000236b
purpose, Na1,K1-ATPase activity was assayed with aEntacapone 0.00127560.000268a
SKF 835661entacapone 0.00233260.000302b biochemical method. Basal Na1,K1-ATPase activity in
Nitecapone 0.00017760.000155a rat renal proximal tubules was 100.2 6 5.6 nmol Pi/mgSKF 835661nitecapone 0.00114660.000216b
protein/min, and, as shown in Figure 10, all three nitro-
Values are mean 6 SEM. catechol compounds produced a concentration-depen-Significantly different from control values (a P , 0.05) and values for corre-
sponding controls (b P , 0.05). dent inhibition of enzyme activity. Nitecapone was the
most potent compound with the lowest IC25 value, 10
(7, 15) mmol/L. No significant difference was observed in
the IC25 values for tolcapone 82 (range 61 to 112) mmol/Ldent manner. This effect was due to the transport of and entacapone 47 (27 to 83) mmol/L.
sodium across the basolateral membrane mediated by
Na1,K1-ATPase, as indicated by complete prevention
DISCUSSIONby ouabain (100 mmol/L) and removal of sodium from
medium bathing the apical side of the monolayer (data The results presented here show that treatment of rats
with tolcapone, entacapone, and nitecapone, at doses pro-not shown). Pretreatment with dopamine applied from
Vieira-Coelho et al: Nitrocatechol inhibitors 1691
intervene in the generation of a decrease in tubular sodium
absorption. Given the structural similarities between do-
pamine and the nitrocatechol derivatives tolcapone, en-
tacapone, and nitecapone (Fig. 1), it was hypothesized
that these compounds could interact with dopamine re-
ceptors, leading to stimulation of events associated with
activation of these receptors. This is quite likely to be the
case considering that all nitrocatechol derivatives dis-
placed [3H]-Sch 23390 from rat renal cortical membranes
and exerted marked stimulation of adenylyl cyclase. The
mechanisms underlying natriuresis by tolcapone, entaca-
pone, and nitecapone appear to result from the inhibition
of Na1/H1 exchanger and Na1,K1-ATPase.
The initial studies on the natriuretic effects by nitrocat-
echol derivatives showed that enhanced natriuresis by
nitecapone was accompanied by a parallel reduction of
Na1,K1-ATPase activity, and these effects were pre-
vented by selective blockade of dopamine D1-like recep-
tors [11]. Subsequently, others showed that entacapone
also produced natriuresis, this being prevented by block-
ade of dopamine D1-like receptors, although effects on
Na1,K1-ATPase activity were not reported [12, 13]. Both
groups of researchers suggested that the natriuresis dur-
ing COMT inhibition was most likely related to enhance-
ment of the availability of renal dopamine, although
parallel increases in the urinary excretion of the amine
were not shown. The authors considered that the in-
crease in the urinary excretion of DOPAC could be
taken as an indication of an increase in the availability
of dopamine. However, Hansell, Odlind, and Mannisto
showed that CGP 28014, a noncatechol COMT inhibitor,
increased the urinary excretion of both dopamine and
DOPAC and reduced that of HVA, but failed to produce
natriuresis [12]. The apparent discrepancy between the
results presented here and those reported by Eklof et al
was related to our ability to show an increase in the
urinary excretion of dopamine after the administration
of nitecapone [11]. However, the percentage reduction
Fig. 8. (A) Changes in the short circuit current (Isc; mA/cm2) induced in the urinary excretion of HVA and inhibition of renalby amphotericin B (0.1 to 1.0 mg/mL) in monolayers of OK cells. (B)
COMT was quite similar in both studies. This contrastsEffect of dopamine (1 mmol/L) in the absence and the presence of SKF
83566 (1 mmol/L) on changes in Isc induced by amphotericin B (0.6 with findings with entacapone and tolcapone, in which
mg/mL) in monolayers of OK cells. Columns represent mean 6 SEM for the same degree of COMT inhibition and decrease(N 5 4). Significantly different from corresponding control values (*P ,
in the urinary excretion of HVA, no significant increase0.05) and values for dopamine (#P , 0.05).
in the urinary excretion of dopamine was observed. On
the other hand, these findings are quite similar to those
reported for entacapone in previous studies [12, 13].
ducing an effective inhibition of renal COMT (.95% Thus, it is likely that factors exclusively related to niteca-
inhibition), was accompanied by marked increases in pone may also influence this particular behavior. One
the urinary excretion of sodium. Pretreatment with Sch possibility that should be considered is the difference in
23390 prevented this natriuretic effect, which suggested the pharmacokinetics and distribution of these nitrocate-
the involvement of D1-like receptors. Since natriuresis chol derivatives [26, 27]. In fact, nitecapone has the short-
induced by nitrocatechol COMT inhibitors did not corre- est half-life among the known nitrocatechol derivatives,
late well with increases in the urinary excretion of dopa- which are excreted mainly by the kidney [28]. Thus, it
mine, it was hypothesized that mechanisms other than might be possible that higher concentrations of niteca-
pone were attained at the kidney.the enhancement of renal dopamine availability might
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Although an enhancement of renal dopamine due to
nitecapone could be partially responsible for the ob-
served natriuresis, this is quite unlikely for tolcapone
and entacapone. As mentioned previously in this article,
natriuresis by tolcapone and entacapone did not corre-
late with changes in the urinary excretion of dopamine,
although they were sensitive to the D1-like receptor an-
tagonist Sch 23390. Hansell, Odlind, and Mannisto [12]
and Odlind et al [13] did not show that the natriuresis
by entacapone was accompanied by inhibition of renal
Na1,K1-ATPase activity, as was the case for nitecapone.
However, these authors suggested that this could be case
since the natriuretic effect of dopamine is thought to
depend on the inhibition of sodium pump activity
[12, 13]. After observing that tolcapone, entacapone, and
nitecapone were endowed with the ability to displace
[3H]-Sch 23390 from rat renal cortex membranes, it was
decided to measure cAMP accumulation in OK cells
in culture. In fact, cAMP resulting from stimulation of
adenylyl cyclase has been shown to be one of the second
messengers in the action of dopamine at the kidney level
[1, 29]. To exclude the possibility that effects of nitrocate-
chol derivatives on cAMP accumulation could be related
to increases in the availability of endogenous dopamine,
it was felt more appropriate to perform these experi-
ments in OK cells. This renal cell line expresses D1-like
receptors, the activation of which results in increases in
cAMP [18]. In addition, these cells were shown not to
store endogenous dopamine, despite that they are en-
dowed with the ability to form dopamine from exoge-
nous L-DOPA [30]. Taking advantage of this cellular
preparation, we were able to demonstrate that tolca-
pone, entacapone, and nitecapone were able to increase
cAMP accumulation, which was sensitive to SKF 83556,
a D1-like receptor antagonist. This strongly supports the
view that interaction with D1-like receptors results in
stimulation of transducing pathways. In parallel, the
decrease in Na1/H1 exchange and Na1,K1-ATPase ac-
tivities by tolcapone, entacapone, and nitecapone adds
further evidence that these compounds stimulate mecha-
nisms that limit renal tubular reabsorption of sodium
that ultimately result in a natriuresis.
The clinical utilization of COMT inhibitors is now
limited to entacapone as an adjunct in levodopa therapy
in Parkinson’s disease. The most common doses em-
ployed range from 100 to 200 mg, which are much less
than the doses that were used in the present study and
b
Fig. 9. Effect of tolcapone, entacapone, and nitecapone (30 and
100 mmol/L) in the absence and the presence of SKF 83566 (1 mmol/L)
on changes in Isc induced by amphotericin B (0.6 mg/mL) in monolayers
of OK cells. The columns represent mean 6 SEM (N 5 4). *P , 0.05,
significantly different from corresponding control values; #P , 0.05,
values for the corresponding nitrocatechol derivative.
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Fig. 10. Effect of increasing concentrations
of tolcapone, entacapone, and nitecapone on
Na1,K1-ATPase activity in renal proximal tu-
bules. Basal Na1,K1-ATPase activity was
100.2 6 5.6 nmol Pi/mg protein/min. Values
are mean 6 SEM (N 5 4).
by other authors [11–13]; 30 mg/kg is 10- to 20-fold the It is concluded that direct stimulation of D1-like dopa-
dose used in patients. Thus, it is expected that natriuresis mine receptors associated with inhibition of Na1/H1 ex-
may not be observed in patients at therapeutic doses. change and Na1,K1-ATPase activities by nitrocatechol
On the other hand, the doses that were employed here COMT inhibitors may contribute to natriuresis produced
provide marked inhibition of COMT and are expected by these compounds.
to originate very high levels of the parent compounds
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Sch 23390, stimulate cAMP accumulation, and inhibit
Na1/H1 exchange and Na1,K1-ATPase activities. To our
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